This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Aptar Pharma discusses intranasal administration for CNS therapeutics
Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
New solutions for pre-clinical discovery in respiratory healthcare
Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations
Improving Intranasal Sprays for Respiratory Viral Infections
Publications, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation
The Go-To Drug Delivery Expert
Brochures, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Product Solutions
